PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline.

The market appears to be short-sighted.

Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make ​its Claude AI model available to ‌over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across.

The deal helps solidify Anthropic's commitment to the life sciences sector as it targets more enterprise clients.

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

The stocks listed here yield between 3.8% and 7.4%. Their valuations are incredibly low when compared to the S&P 500.

Rose's Income Garden portfolio targets high-yield, quality dividend stocks across 10 sectors, emphasizing value and credit quality. Current high-yield sector picks include MO, BMY, AES, VZ, GPC, and VICI, each with yields above 4.5% and favorable valuation or growth profiles. RIG's forward yield exceeds 6.09%, with YTD performance at 8.39%, outpacing SPY's 0.99% yield and focusing on undervalued dividend payers.

Bristol Myers Squibb this week announced a partnership with Hengrui Pharma to develop drugs together. American and European biopharmaceutical companies are increasingly looking to China for their next blockbusters.